Skip to content
GLOBALANCE INTELLIGENCEThe economy ahead.
This Week Index 28/100 Sign in
Money & Investments › GI 100 Index
The Great Value ShiftInvestment ThemesGI 100 IndexGI PortfolioStart Future Check
AI FOOTPRINTlimitedASSESSMENT 2026GLOBALANCEINTELLIGENCE
Globalance AI Footprint

Assessment as of November 2026 · next assessment 2027.

Result of the assessment by the Globalance research team under the published methodology. Not a certification or quality label.

How we assess ›

How this rating is builtVideo · 0:52
GI 100 Index · Profile

Merck & Co

USAAdoptersAssignment FullData quality Medium

Key messagelimited AI Footprint

Merck uses artificial intelligence widely in research, clinical trials, manufacturing and administration and had an important application for study reports tested by an independent assessor, but beyond general principles it discloses little about who in the company is responsible for AI and how new AI applications are reviewed and approved. No harm caused by Merck's own AI is documented in the period reviewed; two minor data protection cases concerned a website tracking lawsuit and a data incident at a service provider.

Opportunities

  • Safetysolid

    The CSR application iRAP was tested by an independent assessor in the Global AI Assurance Pilot for faithfulness to the source and hallucinations, and Merck documents human review by medical writers (S13, S11, S12).

    The CSR application iRAP was tested by an independent assessor in the Global AI Assurance Pilot for faithfulness to the source and hallucinations, and Merck documents human review by medical writers (S13, S11, S12). The cybersecurity programme is described in the 10-K with external assessments, red-teaming and tabletop exercises, supplier assessment and an escalation path (S03, S04). As a limitation, the independent test covers only one use case and explicitly excluded AI security (prompt injection, data leakage) and bias (S13); for manufacturing, trial recruitment and the agent platform there is no evidence of validation. The two data protection cases in the window are minor and have no AI reference (S23, S24). Hence solid.

Risks

  • Responsibilitylimited

    It is documented that the board treats AI as a priority in 2026 within its digital strategy, that cybersecurity sits with the Audit Committee and data protection with the Governance Committee (S05, S06); an explicit AI responsibility of a committee or a named AI responsibility is, however, not disclosed.

    It is documented that the board treats AI as a priority in 2026 within its digital strategy, that cybersecurity sits with the Audit Committee and data protection with the Governance Committee (S05, S06); an explicit AI responsibility of a committee or a named AI responsibility is, however, not disclosed. On governance there are only the AI principles of 2023 without bodies or approval processes (S01), a policy on generative AI mentioned in the press (S18) and a job posting for an AI ethics and governance team (S22). Embedding is shown in training information (S15, S11) and in the certified data protection programme (S20, S08), but not in AI-specific metrics, audits or complaints channels. Hence limited, at the level of principles; the gap in the Ethics & Values chapter of the Impact Report may conceal existing information.

  • Transparencylimited

    The principles promise to disclose when people interact with AI and to make models understandable (S01), without any documented implementation, for example for the field force chatbot or AI-generated content (S15).

    The principles promise to disclose when people interact with AI and to make models understandable (S01), without any documented implementation, for example for the field force chatbot or AI-generated content (S15). The privacy page does not mention AI or automated decisions (S20). A positive point is the public case study on the CSR application with information on how it works and its limitations (S13), but it concerns only one system. Model cards, transparency reports and information on training data are missing. Hence limited.

  • Risk area

    Generative AI in regulatory documents and clinical development

  • Risk area

    AI in manufacturing and quality inspection of vaccines and medicines

  • No serious controversy recorded.

What lies behind the assessment

Research of 3 November 2026
43searches
30pages and documents read
9primary documents
2controversies checked
5open points, named openly
The full research: pillars, evidence, controversies and open points
AI Footprint · Adopter · As of 3 November 2026
Merck & CoOverall rating: limited

Merck had its AI application for clinical study reports tested by an independent assessor and describes a cyber programme with red-teaming. Who is responsible for AI in the group and how new AI applications are approved is barely disclosed.

Responsibility

40 %
limitedsolidstrong

AI is a board priority, but responsibilities and approvals are not disclosed.

  • +AI is among the board's priorities in 2026 Source ↗
  • +Seven AI principles since May 2023 Source ↗
  • +Certified data protection programme with an external complaints channel Source ↗
  • –No committee with explicit responsibility for AI
  • –No published approval process for AI
All sources for this pillar (12)

Safety

40 %
limitedsolidstrong

One AI application is independently tested, but further rollouts lack evidence of testing.

  • +Independent test of the AI for study reports Source ↗
  • +Human review of AI drafts by medical writers Source ↗
  • +Cyber programme with external assessments and red-teaming Source ↗
  • –Test explicitly excluded AI security and bias Source ↗
  • –No evidence of testing for the agent platform and manufacturing
All sources for this pillar (12)
What is missing for “strong”

These steps are in the company’s own hands.

1Responsibility
Disclose AI responsibility and approval

Name a committee and a person responsible for AI and publish the approval process for in-house and purchased AI.

2Safety
Extend testing to all core applications

Publish independent tests, including security and bias, also for manufacturing, trial recruitment and the agent platform.

3Transparency
Label and describe AI use

Label AI-generated content, disclose AI in the privacy notices and publish system descriptions of the core applications.

Context: 101 companies assessed

Distribution of overall ratings, no ranking
strong
none yet
solid
limited
← Merck & Co is one of 66

No company reaches “strong” today. Disclosure on how companies handle AI is still young across the market.

Controversies
2 2 minor

No deduction for controversies.

Largest risk area
Errors in AI-drafted study reports

Merck has drafts of clinical study reports produced with generative AI and plans to extend this to its late-stage pipeline; the independent test did not cover security and bias.

How thoroughly assessed
32 Evidence

9 primary documents read, 43 searches.

Read the full reasoning and all sources
Merck & Co · Full reasoning

Independently tested AI for study reports, but little documented AI governance

Overall rating “limited”. No deduction for controversies. The superscript numbers link directly to the source.

1 · Responsibility

limitedWeight 40%

Merck names AI as a board priority and has AI principles from 2023, but discloses no responsible committee, no persons responsible for AI and no approval process.

What is documented
  • The board's 2026 priorities include digital technologies, including AI1
  • Cybersecurity sits with the Audit Committee, data protection with the Governance Committee1 2
  • Seven AI principles from May 2023 refer to internal AI guidelines4
  • According to the press, there is a formal policy on generative AI with technical guardrails5
  • A company-wide training programme on generative and agentic AI covers responsible use8 9
  • The data protection programme is certified under APEC CBPR and BCR and offers an external complaints channel via BBB National Programs10 11
The case against
No documented governance
  • No committee with explicit AI responsibility and no named person responsible for AI are disclosed1
  • Approval processes, risk classification and rules for purchased and agentic AI such as the Gemini agent platform are not published7
  • A global team for AI risk assessment is known only from a job posting6
Missing metrics and audits
  • No AI-specific metrics, external audits or complaints channels were found
  • The Ethics & Values chapter of the Impact Report remained unreadable and may contain further information12
Sources for Responsibility (12)
  1. Merck & Co., Inc. (merck.com): 2026 Merck Proxy Statement · 8 April 2026 · primary source
  2. Merck & Co., Inc. (SEC EDGAR): Definitive Proxy Statement (DEF 14A) 2025 · 9 April 2025 · primary source
  3. Merck & Co., Inc. (SEC EDGAR): Definitive Proxy Statement (DEF 14A) 2024 · 28 May 2024 · primary source
  4. Merck Sharp & Dohme (msd.com): Developing and using AI ethically and responsibly · 1 May 2023 · secondary source
  5. Fortune: How Merck leveled up its cybersecurity strategy since the NotPetya cyberattack that led to a $1.4bn dispute · 22 October 2024 · secondary source
  6. Dice (job posting by Merck & Co., Inc.): Artificial Intelligence (AI) Ethics and Governance Senior Specialist · 27 May 2026 · secondary source
  7. Merck & Co., Inc. (merck.com): Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation · 22 April 2026 · secondary source
  8. Merck & Co., Inc. (merck.com): 5 ways we're transforming artificial intelligence into impact · 9 January 2026 · secondary source
  9. Merck & Co., Inc. (merck.com): Merck Expands Innovative Internal Generative AI Solutions Helping to Deliver Medicines to Patients Faster · 25 June 2025 · primary source
  10. Merck Sharp & Dohme (msdprivacy.com): MSD Privacy – Our Commitment to Privacy (US) · 5 July 2026 · primary source
  11. Merck & Co., Inc. (merck.com): Purpose for Progress: Merck Impact Report Summary 2025/2026 · 1 August 2026 · primary source
  12. Merck & Co., Inc. (merck.com): Purpose for Progress: Merck Impact Report 2025/2026 · 1 August 2026 · primary source

2 · Safety

solidWeight 40%

Merck had its AI for study reports independently tested for hallucinations and describes a cyber programme with external assessments and red-teaming, but the test covers only one application.

What is documented
  • In the Global AI Assurance Pilot, an independent assessor tested the iRAP application for faithfulness to the source, contradictions and hallucinations1
  • The AI drafts of clinical study reports are reviewed by medical writers2 3
  • Item 1C describes a CISO-led programme with external assessments, tabletop and red-teaming exercises and supplier assessment5 6
  • Cybersecurity is overseen by the Audit Committee; incidents are escalated to an Incident Assessment Team5
  • According to the press, Merck relies on zero trust, attack emulation by third parties and guardrails against model training on company data7
The case against
Limited testing coverage
  • The independent test covers only one use case and one test dataset and excluded prompt injection, data leakage and bias1
  • There is no evidence of validation for AI in manufacturing, trial recruitment, the supply chain and on the agent platform12
  • Item 1C was read only via an account, not directly from the SEC filing5
Data protection cases without AI reference
  • Since 2023 a class action has been pending against the subsidiary Intervet (HomeAgain) over tracking software on its website11
  • An incident at the service provider Graebel affected data of Merck employees in 2025; Merck reported it to the authorities9 10
Sources for Safety (12)
  1. AI Verify Foundation (Singapore) / Resaro: MSD x Resaro – Global AI Assurance Pilot Case Study · 1 May 2025 · primary source
  2. Merck & Co., Inc. (merck.com): Merck Expands Innovative Internal Generative AI Solutions Helping to Deliver Medicines to Patients Faster · 25 June 2025 · primary source
  3. McKinsey & Company: With gen AI, Merck and McKinsey transform clinical authoring · 27 June 2025 · secondary source
  4. Merck Sharp & Dohme (msd.com): Developing and using AI ethically and responsibly · 1 May 2023 · secondary source
  5. Board Cybersecurity (reproduced from the Merck & Co. 10-K): Merck & Co., Inc. 10-K Item 1C. Cybersecurity – 2026-02-24 · 24 February 2026 · primary source
  6. Board Cybersecurity (reproduced from the Merck & Co. 10-K): Merck & Co., Inc. 10-K Cybersecurity GRC – 2026-02-24 · 24 February 2026 · primary source
  7. Fortune: How Merck leveled up its cybersecurity strategy since the NotPetya cyberattack that led to a $1.4bn dispute · 22 October 2024 · secondary source
  8. Merck & Co., Inc. (merck.com): Purpose for Progress: Merck Impact Report Summary 2025/2026 · 1 August 2026 · primary source
  9. Levi & Korsinsky, LLP (AccessNewswire): Merck Sharp & Dohme LLC Data Breach under Investigation by Levi & Korsinsky, LLP · 2 December 2025 · secondary source
  10. Claim Depot: Merck Data Breach: Financial Account Information Exposed · 17 November 2025 · secondary source
  11. Bloomberg Law: Merck Unit Faces Online Privacy Case That Tests New Legal Theory · 20 November 2023 · secondary source
  12. Merck & Co., Inc. (merck.com): Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation · 22 April 2026 · secondary source

3 · Transparency

limitedWeight 20%

Merck promises in its principles to disclose AI interactions, but apart from a case study on its study report AI it publishes no system descriptions, model cards or data information.

What is documented
  • The principles promise to disclose when people interact with AI and to make models understandable1
  • The case study on the study report AI publicly describes its scope, test methods and limitations5
  • Areas of AI use are described in company articles and in the Impact Report2 3
The case against
Implementation not documented
  • No labelling is documented for the field force chatbot and AI-generated content for healthcare professionals and patients2
  • The privacy page does not mention AI or automated decisions4
  • Model and system cards, a transparency report and information on training data are missing; the models of the internal platform are known only from secondary sources7
Sources for Transparency (8)
  1. Merck Sharp & Dohme (msd.com): Developing and using AI ethically and responsibly · 1 May 2023 · secondary source
  2. Merck & Co., Inc. (merck.com): 5 ways we're transforming artificial intelligence into impact · 9 January 2026 · secondary source
  3. Merck & Co., Inc. (merck.com): Purpose for Progress: Merck Impact Report 2025/2026 · 1 August 2026 · primary source
  4. Merck Sharp & Dohme (msdprivacy.com): MSD Privacy – Our Commitment to Privacy (US) · 5 July 2026 · primary source
  5. AI Verify Foundation (Singapore) / Resaro: MSD x Resaro – Global AI Assurance Pilot Case Study · 1 May 2025 · primary source
  6. Fortune: How Merck leveled up its cybersecurity strategy since the NotPetya cyberattack that led to a $1.4bn dispute · 22 October 2024 · secondary source
  7. IntuitionLabs: GPTeal: Merck's Generative AI Strategy for Pharma R&D · 10 October 2025 · secondary source
  8. Merck & Co., Inc. / Mayo Clinic (Q4 investor platform): Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine · 18 February 2026 · secondary source

4 · Why the harm rule does not apply

The harm rule does not apply: no AI-related harm, authority decision or settlement is documented in the review period. The two data protection cases are minor and have no AI reference.

5 · Controversies (2)

6 · What remains open

  • Explicit AI responsibility at board level and named persons responsible for AI
  • Current AI policy, risk classification and approval process, also for purchased and agentic AI
  • Validation and security evidence for AI in manufacturing, trial recruitment, sales and on the agent platform
  • Content of the Ethics & Values chapter of the Impact Report and of any AI risk factor in the 10-K
  • Status of the HomeAgain class action

7 · How it was assessed

Cut-off date: 3 November 2026 · 43 searches, 30 fetches.

Primary documents read (9)
  • Form 10-K FY2025 (Item 1, pipeline section; Item 1A/1C/3 truncated)
  • Form 10-K FY2025 Item 1C (reproduced via board-cybersecurity.com, two pages)
  • Proxy Statements 2026, 2025 and 2024 (board oversight, skills matrix, agenda items)
  • Form 10-Q Q2 2026 (up to character 100,000)
  • Purpose for Progress Impact Report 2025/2026 (extract) and Summary 2025/2026; MSD Impact Report 2024/2025 (extract)
  • AI principles «Developing and using AI ethically and responsibly» (May 2023)
  • MSD Privacy (US) and Values and Standards
  • Press releases: CSR platform (2025-06-25), Mayo Clinic (2026-02-18), Google Cloud (2026-04-22); article «5 ways» (2026-01-09)
  • Case study MSD x Resaro (AI Verify Foundation, Global AI Assurance Pilot)

Research of 3 November 2026 under Globalance AI Footprint rulebook version 0

We assess documented practice in dealing with AI; this is not an investment recommendation. Three pillars, weights 40/40/20, harm rule.

Research of 3 November 2026 under Globalance AI Footprint rulebook version 0. Documented observations from public sources, no investment recommendation.

Important Notice. This material is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any financial instrument, nor does it constitute investment advice or a recommendation. The GI 100 Index is a rules-based strategy index of Globalance Bank. Investments involve risk, including the loss of capital invested. The final product documents (including FinSA) shall prevail in all cases.

Your company? Information on inclusion in the GI 100 Index →

What comes next